Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Ardelyx in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the biopharmaceutical company will post earnings of ($0.13) per share for the year. The consensus estimate for Ardelyx’s current full-year earnings is ($0.17) per share.

A number of other equities analysts also recently issued reports on ARDX. Citigroup cut their price target on Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Jefferies Financial Group cut their target price on Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, January 2nd. Finally, HC Wainwright reissued a “neutral” rating and issued a $5.50 price target on shares of Ardelyx in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.25.

Ardelyx Stock Up 2.9 %

Shares of NASDAQ ARDX opened at $5.05 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.03 and a quick ratio of 3.87. Ardelyx has a 1 year low of $4.32 and a 1 year high of $10.13. The stock has a market capitalization of $1.20 billion, a P/E ratio of -16.83 and a beta of 0.85. The company has a 50-day moving average price of $5.15 and a 200-day moving average price of $5.65.

Insiders Place Their Bets

In related news, CEO Michael Raab sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $5.91, for a total value of $147,750.00. Following the transaction, the chief executive officer now owns 1,210,108 shares in the company, valued at approximately $7,151,738.28. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David P. Rosenbaum sold 27,172 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $5.95, for a total value of $161,673.40. Following the completion of the sale, the insider now directly owns 153,616 shares of the company’s stock, valued at $914,015.20. This represents a 15.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 218,358 shares of company stock valued at $1,189,516. Insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its position in Ardelyx by 142.8% during the second quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company’s stock worth $23,735,000 after purchasing an additional 1,883,995 shares during the period. Rubric Capital Management LP boosted its holdings in Ardelyx by 68.5% in the 3rd quarter. Rubric Capital Management LP now owns 3,060,191 shares of the biopharmaceutical company’s stock worth $21,085,000 after buying an additional 1,243,606 shares during the period. Eventide Asset Management LLC lifted its position in shares of Ardelyx by 11.2% during the third quarter. Eventide Asset Management LLC now owns 7,413,049 shares of the biopharmaceutical company’s stock worth $51,076,000 after acquiring an additional 746,067 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Ardelyx in the third quarter worth $3,445,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of Ardelyx by 375.9% in the second quarter. Squarepoint Ops LLC now owns 460,689 shares of the biopharmaceutical company’s stock worth $3,414,000 after acquiring an additional 363,894 shares during the period. Hedge funds and other institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.